Figure 4.
Effect of recombinant MC148 and vMIP-II on calcium mobilization on a panel of cell lines stably transfected with humane chemokine receptors. 10−7 M MC148, vMIP-II, or vehicle was added to the cells at 50 s, followed by a submaximal dose of an appropriate endogenous human chemokine at 150 s. The height of the response with the endogenous ligand was measured, and the heights in the experiments with MC148 and vMIP-II were expressed as percent of the height in the experiment with the vehicle. A representative example of each experiment is shown to the left, whereas the box diagram to the right shows the average inhibition with SEM as indicated. Asterisks (*) indicate statistically significant inhibition (P < 0.05). The chemokine concentrations used were: CCR1, 10−10 M RANTES; CCR2, 10−8 M MCP-1; CCR3, 10−9 M MCP-3; CCR4, 10−9 M macrophage-derived chemokine; CCR5, 10−9 M RANTES; CCR6, 10−8 M liver-activated and -regulated chemokine; CCR7, 10−9 M secondary lymphoid tissue chemokine; CCR8, 10−8.5 M I-309; CCR9, 10−7 M thymus-expressed chemokine; CXCR1, 10−9 M IL-8; CXCR2, 10−9 M IL-8; CXCR3, 10−10 M I-TAC; CXCR4, 10−10 M SDF-1α; CXCR5, 10−10 M B cell–attracting chemokine 1; XCR1, 10−7 M murine lymphotactin; and CX3CR1, 10−9 M fractalkine.